Reversible busulfan-induced ovarian failure.
A 26-yr-old woman with chronic myeloid leukemia developed busulfan-induced ovarian failure. The ovarian failure was manifested by amenorrhea and climacteric symptoms and was verified by elevated plasma levels of luteinizing and follicle-stimulating hormones concomitant with low 17 beta-estradiol levels. The amenorrhea proved to be reversible when, during hematological relapse one year later, the patient was found to be four months pregnant. The busulfan which she was receiving at that time was stopped and amniocentesis revealed a normal karyotype. The remainder of the pregnancy was unremarkable and was terminated by the normal delivery of a healthy child.
Shalev
O
O
Department of Medicine, Hadassah University Hospital, Mount Scopus, Jerusalem, Israel.
Rahav
G
G
Milwidsky
A
A
D000328:Adult; D000568:Amenorrhea / Q000097:blood / Q000139:chemically induced* / Q000188:drug therapy; D002066:Busulfan / Q000009:adverse effects* / Q000627:therapeutic use; D004958:Estradiol / Q000031:analogs & derivatives / Q000097:blood / Q000627:therapeutic use; D004966:Estrogens, Conjugated (USP) / Q000627:therapeutic use; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D006801:Humans; D007231:Infant, Newborn; D007951:Leukemia, Myeloid / Q000150:complications / Q000188:drug therapy*; D007986:Luteinizing Hormone / Q000097:blood; D008594:Menopause, Premature; D009640:Norethindrone / Q000031:analogs & derivatives / Q000627:therapeutic use; D000077563:Norethindrone Acetate; D009644:Norgestrel / Q000627:therapeutic use; D011247:Pregnancy; D011252:Pregnancy Complications, Neoplastic
D004966:Estrogens, Conjugated (USP); D009644:Norgestrel; D004958:Estradiol; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone; D000077563:Norethindrone Acetate; D002066:Busulfan; D009640:Norethindrone